Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis

Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis

BACKGROUND. The approved capecitabine regimen as monotherapy in metastatic breast cancer (MBC) is 1,250 mg/m(2) twice daily for 2 weeks on and 1 week off (Cint). Dose modifications are often required because of severe hand-foot syndrome (HFS). We tested a continuous regimen with a lower daily dose b...

Olles dieđut

Furkejuvvon:
Bibliográfalaš dieđut
Váldodahkkit: Martín, Miguel, Martínez, Noelia, Ramos, Manuel, Calvo, Lourdes, Lluch, Ana, Zamora, Pilar, Muñoz, Montserrat, Carrasco, Eva, Caballero, Rosalía, García-Sáenz, José Ángel, Guerra, Eva, Caronia, Daniela, Casado, Antonio, Ruíz-Borrego, Manuel, Hernando, Blanca, Chacón, José Ignacio, De la Torre-Montero, Julio César, Jimeno, María Ángeles, Heras, Lucía, Alonso, Rosario, De la Haba, Juan, Pita, Guillermo, Constenla, Manuel, González-Neira, Anna
Materiálatiipa: Teaksta
Giella:eaŋgalasgiella
Almmustuhtton: AlphaMed Press 2015
Fáttát:
Clinical Trial Results
Liŋkkat:https://pmc.ncbi.nlm.nih.gov/articles/PMC4319639/
https://pubmed.ncbi.nlm.nih.gov/25601966
http://dx.doi.org/10.1634/theoncologist.2014-0379
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Interneahtta

https://pmc.ncbi.nlm.nih.gov/articles/PMC4319639/
https://pubmed.ncbi.nlm.nih.gov/25601966
http://dx.doi.org/10.1634/theoncologist.2014-0379

Geahča maid